By Fineline Cube 
Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of €13.405 billion (USD 15.73 billion), representing 4.1% year-over-year growth, while its pharmaceuticals division delivered €4.249 billion (USD 4.98 billion) in revenue, remaining roughly flat compared to the same period last year.
Financial Performance Overview
| Metric | Q1 2026 | YOY Change |
|---|---|---|
| Group Sales | €13.405 billion | +4.1% |
| Pharmaceuticals Revenue | €4.249 billion | ~Flat |
| North America | €1.465 billion | +15.2% |
| Europe/MEA | €1.371 billion | -14.7% |
| Asia-Pacific | €1.170 billion | -1.3% |
| Latin America | €243 million | +9.5% |
Key Product Performance Analysis
Growth Drivers
| Product | Q1 2026 Sales | YOY Change | Key Drivers |
|---|---|---|---|
| Nubeqa (darolutamide) | €749 million | +57.1% | Sustained volume growth across all regions, particularly U.S. and Europe; slight deceleration due to U.S. Inflation Reduction Act pricing effects |
| Kerendia (finerenone) | €274 million | +84.2% | Substantial volume increases in U.S. and China |
| Adalat (nifedipine) | €171 million | +25.6% | Strong market uptake in antihypertensive segment |
Declining Products
| Product | Q1 2026 Sales | YOY Change | Key Challenges |
|---|---|---|---|
| Eylea (aflibercept) | €623 million | -20.5% | Generic erosion in Canada and Europe affecting pricing; partially offset by Eylea 8mg launch (46% of total Eylea sales) |
| Aspirin (secondary MI prevention) | €13日晚间 | -28.5% | Impact from China’s volume-based procurement (VBP) tender rounds |
| Stivarga (regorafenib) | €76 million | -17.4% | VBP-related pricing pressure in China |
Regional Performance Dynamics
North America Strength (+15.2%)
- Primary growth engine for pharmaceuticals division
- Nubeqa momentum driven by strong U.S. prostate cancer market adoption
- Kerendia expansion benefiting from cardiovascular risk reduction positioning
- IRA headwinds: Inflation Reduction Act beginning to impact pricing, particularly for Nubeqa
Europe/MEA Weakness (-14.7%)
- Generic competition significantly impacting Eylea pricing
- Market access challenges across multiple therapeutic areas
- Currency headwinds potentially contributing to reported decline
Asia-Pacific Stability (-1.3%)
- Mixed performance: Kerendia showing strong China growth offset by VBP impacts on legacy products
- China VBP effects: Aspirin and Stivarga facing significant pricing pressure from procurement rounds
- Emerging market resilience: Partial offset from other Asia-Pacific markets
Strategic Product Highlights
Eylea Franchise Evolution
- Eylea 8mg launch success: New extended-dosing formulation accounts for 46% of total Eylea sales
- Franchise defense strategy: Higher-concentration formulation designed to maintain market share amid biosimilar competition
- Pricing pressure management: Innovation helping mitigate generic erosion impact
Oncology Portfolio Resilience
- Nubeqa leadership: Maintaining strong growth trajectory despite IRA-related pricing headwinds
- Prostate cancer market expansion: Continued volume growth indicating sustained market penetration
- Therapeutic area focus: Oncology remains key growth pillar for Bayer’s pharmaceutical strategy
Market Context & Forward Outlook
- IRA implementation: U.S. Inflation Reduction Act beginning to affect innovative drug pricing, with potential for increased impact in coming quarters
- China VBP expansion: Volume-based procurement continuing to pressure legacy product revenues, requiring portfolio rebalancing
- Innovation pipeline importance: Success of newer products (Nubeqa, Kerendia) critical to offsetting generic erosion on established brands
- Geographic diversification: Regional performance disparities highlighting need for balanced global strategy
The Q1 results reflect Bayer’s transition phase, where innovative products are driving growth while legacy assets face increasing pricing and competitive pressures across key markets.
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, market dynamics, and strategic outlook. Actual results may differ due to risks including regulatory changes, competitive pressures, and macroeconomic factors.-Fineline Info & Tech